Quote:
Here is one of several instances where Leronlimab is mentioned in the article from Taylor and Francis online, a database of scientific journals. This particular journal, is aptly titled "Expert Opinion on Investigational Drugs." The Journal's overview is daunting and comprehensive: "Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development."
INNATE IMMUNITY AS A TARGET FOR NOVEL THERAPEUTICS IN TRIPLE NEGATIVE BREAST CANCER
Page 117: The CCR5 antagonist leronlimab has demonstrated significant reduction of metastatic burden in preclinical models of metastatic breast cancer.
One last fact. This article went through a rigorous process for publication. "All manuscripts submitted to the journal are peer-reviewed in a double-blind fashion."
Here is one of several instances where Leronlimab is mentioned in the article from Taylor and Francis online, a database of scientific journals. This particular journal, is aptly titled "Expert Opinion on Investigational Drugs." The Journal's overview is daunting and comprehensive: "Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development."
INNATE IMMUNITY AS A TARGET FOR NOVEL THERAPEUTICS IN TRIPLE NEGATIVE BREAST CANCER
Page 117: The CCR5 antagonist leronlimab has demonstrated significant reduction of metastatic burden in preclinical models of metastatic breast cancer.
One last fact. This article went through a rigorous process for publication. "All manuscripts submitted to the journal are peer-reviewed in a double-blind fashion."
16
